Photo from archive.org
Drug discovery is challenged by poor predictability of proarrhythmic effects of present cardiac safety screening approaches. The Comprehensive in Vitro Proarrhythmia Assay (CiPA), an FDA directed initiative, is specifically focused… Click to show full abstract
Drug discovery is challenged by poor predictability of proarrhythmic effects of present cardiac safety screening approaches. The Comprehensive in Vitro Proarrhythmia Assay (CiPA), an FDA directed initiative, is specifically focused on improved preclinical assessment of torsade de pointes (TdP) risk. Striving to optimize the drug discovery process, either the usage of iPSC-derived cardiomyocytes or an enlarged cardiac ion channel panel for voltage clamp studies is discussed.
Keywords:
cardiac safety;
package cardiac;
inclusive package;
safety;
safety six;
clamp
Journal Title: Journal of Pharmacological and Toxicological Methods
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Pharmacological and Toxicological Methods
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!